Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: A global developer and manufacturer of minimally invasive medical devices, with a primary focus on interventional cardiology (specifically the TAXUS drug-eluting stent), electrophysiology, neurovascular, and endosurgery. The reporting period was significantly impacted by the launch of the TAXUS stent system in the U.S. and major acquisitions of Advanced Bionics Corporation and Precision Vascular Systems, Inc.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2004 |
Three Months Ended June 30, 2003 |
Six Months Ended June 30, 2004 |
Six Months Ended June 30, 2003 |
|---|---|---|---|---|
| Net Sales | $1,460 | $854 | $2,542 | $1,661 |
| Gross Profit | $1,097 | $619 | $1,887 | $1,200 |
| Gross Margin % | 75.1% | 72.5% | 74.2% | 72.2% |
| Operating Income | $448 | $173 | $712 | $328 |
| Net Income | $313 | $114 | $507 | $211 |
| Diluted EPS | $0.36 | $0.13 | $0.59 | $0.25 |
| Cash from Operations | N/A | N/A | $574 | $354 |
| Cash & Equivalents (End of Period) | $1,000 | $385 | $1,000 | $385 |
| Total Debt (Short + Long Term) | $2,554 | $1,725 | $2,554 | $1,725 |
Note: Total Debt calculated as Commercial Paper + Notes Payable/Current Maturities + Long-term Debt.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 71% year-over-year for the quarter and 53% for the six-month period. This growth was driven primarily by the U.S. launch of the TAXUS drug-eluting stent system, which generated $468 million in sales for the quarter and $566 million for the six months.
- Profitability: Net income surged 175% for the quarter and 140% for the six months. Operating income increased 159% for the quarter.
- Acquisitions: The company completed the acquisition of Advanced Bionics (June 1, 2004) for ~$740 million and Precision Vascular Systems (April 2, 2004) for ~$75 million. These transactions resulted in $64 million in purchased R&D charges for both the quarter and six-month periods.
- Product Recall: A voluntary recall of TAXUS Express(2) and Express(2) coronary stent systems resulted in a $43 million pre-tax inventory write-down and a $35 million sales returns reserve, totaling $57 million in after-tax impact.
- Debt Structure: The company refinanced credit facilities to $2.02 billion in revolving capacity and issued $600 million in senior notes due 2014. Total debt increased significantly to fund acquisitions and operations.
Guidance, Outlook, and Risks
- Market Outlook: Management estimates the 2004 worldwide coronary stent market will approach $4.7 billion, potentially growing to $5 billion in 2005. The company aims to maintain market leadership despite anticipated competition from new drug-eluting stent entrants in 2004-2006.
- Recall Impact: The company is working to replenish inventory in the U.S. and expects to replenish Europe and Inter-Continental markets in Q3 2004. Future sales may be impacted by physician confidence and the availability of inventory.
- Legal Proceedings: Significant ongoing litigation includes patent disputes with Johnson & Johnson (Cordis) regarding stent technology, Medinol Ltd. regarding Express stents, and a U.S. Department of Justice investigation regarding the 1998 NIR ON Ranger stent recall. The company faces potential contingent consideration payments of up to $3.2 billion related to acquisitions.
- Financial Guidance: Management estimates the 2004 effective tax rate will remain at approximately 24%, net of special charges. Capital expenditures for the remainder of 2004 are expected to be approximately $200 million.
Key Investor Verification Points
- Recall Resolution: Verify the timeline and success of inventory replenishment following the TAXUS stent recall and monitor for any further product safety issues.
- Acquisition Integration: Assess the integration progress of Advanced Bionics and Precision Vascular Systems, specifically the regulatory approval status of in-process R&D projects (e.g., bion microstimulator).
- Competitive Landscape: Monitor the market share impact of new competitor drug-eluting stent launches, particularly in Japan (expected 2006 for Boston Scientific) and the U.S. (expected 2006).
- Legal Exposure: Track the outcomes of major patent litigation with Johnson & Johnson and Medinol, as adverse rulings could restrict sales or require royalty payments.
- Debt Servicing: Review the company's ability to service increased debt levels ($2.55 billion total) and manage interest rate exposure through its hedging strategies.